Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2
Updated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle- to low-income countries. Recombinant prote...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/5/498 |
| _version_ | 1827692787167920128 |
|---|---|
| author | Chotiwat Seephetdee Nattawut Buasri Kanit Bhukhai Kitima Srisanga Suwimon Manopwisedjaroen Sarat Lertjintanakit Nut Phueakphud Chatbenja Pakiranay Niwat Kangwanrangsan Sirawat Srichatrapimuk Suppachok Kirdlarp Somnuek Sungkanuparph Somchai Chutipongtanate Arunee Thitithanyanont Suradej Hongeng Patompon Wongtrakoongate |
| author_facet | Chotiwat Seephetdee Nattawut Buasri Kanit Bhukhai Kitima Srisanga Suwimon Manopwisedjaroen Sarat Lertjintanakit Nut Phueakphud Chatbenja Pakiranay Niwat Kangwanrangsan Sirawat Srichatrapimuk Suppachok Kirdlarp Somnuek Sungkanuparph Somchai Chutipongtanate Arunee Thitithanyanont Suradej Hongeng Patompon Wongtrakoongate |
| author_sort | Chotiwat Seephetdee |
| collection | DOAJ |
| description | Updated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle- to low-income countries. Recombinant protein-based subunit vaccines against SARS-CoV-2 have been reported using the receptor-binding domain (RBD) and the prefusion spike trimers (S-2P). Recently, a new version of prefusion spike trimers, named HexaPro, has been shown to possess two RBD in the “up” conformation, due to its physical property, as opposed to just one exposed RBD found in S-2P. Importantly, this HexaPro spike antigen is more stable than S-2P, raising its feasibility for global logistics and supply chain. Here, we report that the spike protein HexaPro offers a promising candidate for the SARS-CoV-2 vaccine. Mice immunized by the recombinant HexaPro adjuvanted with aluminum hydroxide using a prime-boost regimen produced high-titer neutralizing antibodies for up to 56 days after initial immunization against live SARS-CoV-2 infection. Also, the level of neutralization activity is comparable to that of convalescence sera. Our results indicate that the HexaPro subunit vaccine confers neutralization activity in sera collected from mice receiving the prime-boost regimen. |
| first_indexed | 2024-03-10T11:29:55Z |
| format | Article |
| id | doaj.art-9e133e4f2cfe4a6fb3f21915c3c897cb |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T11:29:55Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-9e133e4f2cfe4a6fb3f21915c3c897cb2023-11-21T19:21:13ZengMDPI AGVaccines2076-393X2021-05-019549810.3390/vaccines9050498Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2Chotiwat Seephetdee0Nattawut Buasri1Kanit Bhukhai2Kitima Srisanga3Suwimon Manopwisedjaroen4Sarat Lertjintanakit5Nut Phueakphud6Chatbenja Pakiranay7Niwat Kangwanrangsan8Sirawat Srichatrapimuk9Suppachok Kirdlarp10Somnuek Sungkanuparph11Somchai Chutipongtanate12Arunee Thitithanyanont13Suradej Hongeng14Patompon Wongtrakoongate15Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, ThailandChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, ThailandChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, ThailandChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, ThailandDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, ThailandDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, ThailandUpdated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle- to low-income countries. Recombinant protein-based subunit vaccines against SARS-CoV-2 have been reported using the receptor-binding domain (RBD) and the prefusion spike trimers (S-2P). Recently, a new version of prefusion spike trimers, named HexaPro, has been shown to possess two RBD in the “up” conformation, due to its physical property, as opposed to just one exposed RBD found in S-2P. Importantly, this HexaPro spike antigen is more stable than S-2P, raising its feasibility for global logistics and supply chain. Here, we report that the spike protein HexaPro offers a promising candidate for the SARS-CoV-2 vaccine. Mice immunized by the recombinant HexaPro adjuvanted with aluminum hydroxide using a prime-boost regimen produced high-titer neutralizing antibodies for up to 56 days after initial immunization against live SARS-CoV-2 infection. Also, the level of neutralization activity is comparable to that of convalescence sera. Our results indicate that the HexaPro subunit vaccine confers neutralization activity in sera collected from mice receiving the prime-boost regimen.https://www.mdpi.com/2076-393X/9/5/498HexaProspikeSARS-CoV-2vaccine |
| spellingShingle | Chotiwat Seephetdee Nattawut Buasri Kanit Bhukhai Kitima Srisanga Suwimon Manopwisedjaroen Sarat Lertjintanakit Nut Phueakphud Chatbenja Pakiranay Niwat Kangwanrangsan Sirawat Srichatrapimuk Suppachok Kirdlarp Somnuek Sungkanuparph Somchai Chutipongtanate Arunee Thitithanyanont Suradej Hongeng Patompon Wongtrakoongate Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 Vaccines HexaPro spike SARS-CoV-2 vaccine |
| title | Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 |
| title_full | Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 |
| title_fullStr | Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 |
| title_full_unstemmed | Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 |
| title_short | Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2 |
| title_sort | mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars cov 2 |
| topic | HexaPro spike SARS-CoV-2 vaccine |
| url | https://www.mdpi.com/2076-393X/9/5/498 |
| work_keys_str_mv | AT chotiwatseephetdee miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT nattawutbuasri miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT kanitbhukhai miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT kitimasrisanga miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT suwimonmanopwisedjaroen miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT saratlertjintanakit miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT nutphueakphud miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT chatbenjapakiranay miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT niwatkangwanrangsan miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT sirawatsrichatrapimuk miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT suppachokkirdlarp miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT somnueksungkanuparph miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT somchaichutipongtanate miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT aruneethitithanyanont miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT suradejhongeng miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 AT patomponwongtrakoongate miceimmunizedwiththevaccinecandidatehexaprospikeproduceneutralizingantibodiesagainstsarscov2 |